120 related articles for article (PubMed ID: 23836507)
21. Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer.
Cho S; Kim MJ; Choi YY; Yoo SS; Lee WK; Lee EJ; Jang EJ; Bae EY; Jin G; Jeon HS; Lee SY; Cha SI; Park TI; Kim CH; Park JY
Lung Cancer; 2011 Jul; 73(1):25-31. PubMed ID: 21129811
[TBL] [Abstract][Full Text] [Related]
22. Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection.
Villar S; Le Roux-Goglin E; Gouas DA; Plymoth A; Ferro G; Boniol M; Lereau M; Bah E; Hall AJ; Wild CP; Mendy M; Norder H; van der Sande M; Whittle H; Friesen MD; Groopman JD; Hainaut P
Environ Health Perspect; 2011 Nov; 119(11):1635-40. PubMed ID: 21768053
[TBL] [Abstract][Full Text] [Related]
23. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
24. ALDH1L1 variant rs2276724 and mRNA expression predict post-operative clinical outcomes and are associated with TP53 expression in HBV-related hepatocellular carcinoma.
Zhu G; Liao X; Han C; Liu X; Yu L; Qin W; Lu S; Su H; Chen Z; Liu Z; Liang Y; Huang J; Yu T; Yang C; Huang K; Shang L; Ye X; Li L; Qin X; Xiao K; Peng M; Peng T
Oncol Rep; 2017 Sep; 38(3):1451-1463. PubMed ID: 28714006
[TBL] [Abstract][Full Text] [Related]
25. TP53 rs28934571 polymorphism increases the prognostic risk in hepatocellular carcinoma.
Zhao Y; Zhu C; Chang Q; Yang J; Liu Y; Peng P; Liu C; Cheng R; Chen X; Wu Y; Cheng L; Hu L; Wu X; Yin J
Biomark Med; 2021 Jun; 15(9):615-622. PubMed ID: 34037458
[No Abstract] [Full Text] [Related]
26. TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk.
Lam YK; Yu J; Huang H; Ding X; Wong AM; Leung HH; Chan AW; Ng KK; Xu M; Wang X; Wong N
Hepatology; 2023 Sep; 78(3):727-740. PubMed ID: 36221953
[TBL] [Abstract][Full Text] [Related]
27. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.
Qi LN; Bai T; Chen ZS; Wu FX; Chen YY; De Xiang B; Peng T; Han ZG; Li LQ
Liver Int; 2015 Mar; 35(3):999-1009. PubMed ID: 24461059
[TBL] [Abstract][Full Text] [Related]
28. TP53 codon 72 and intron 3 polymorphisms and mutational status in gastric cancer: an association with tumor onset and prognosis.
Neves Filho EH; Cordeiro DE; Vieira AP; Rabenhorst SH
Pathobiology; 2012; 79(6):323-8. PubMed ID: 22688387
[TBL] [Abstract][Full Text] [Related]
29. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.
Shirabe K; Toshima T; Taketomi A; Taguchi K; Yoshizumi T; Uchiyama H; Harimoto N; Kajiyama K; Egashira A; Maehara Y
Liver Int; 2011 Oct; 31(9):1366-72. PubMed ID: 21745313
[TBL] [Abstract][Full Text] [Related]
30. Depicting the role of TP53 in hepatocellular carcinoma progression.
Villanueva A; Hoshida Y
J Hepatol; 2011 Sep; 55(3):724-725. PubMed ID: 21616106
[TBL] [Abstract][Full Text] [Related]
31. Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.
Zhang W; He H; Zang M; Wu Q; Zhao H; Lu LL; Ma P; Zheng H; Wang N; Zhang Y; He S; Chen X; Wu Z; Wang X; Cai J; Liu Z; Sun Z; Zeng YX; Qu C; Jiao Y
Gastroenterology; 2017 Jul; 153(1):249-262.e2. PubMed ID: 28363643
[TBL] [Abstract][Full Text] [Related]
32. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y;
Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062
[TBL] [Abstract][Full Text] [Related]
33. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
34. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
[TBL] [Abstract][Full Text] [Related]
35. 249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients.
Nogueira JA; Ono-Nita SK; Nita ME; de Souza MM; do Carmo EP; Mello ES; Scapulatempo C; Paranaguá-Vezozzo DC; Carrilho FJ; Alves VA
BMC Cancer; 2009 Jun; 9():204. PubMed ID: 19558663
[TBL] [Abstract][Full Text] [Related]
36. TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3.
Jha P; Jha P; Pathak P; Chosdol K; Suri V; Sharma MC; Kumar G; Singh M; Mahapatra AK; Sarkar C
Exp Mol Pathol; 2011 Apr; 90(2):167-72. PubMed ID: 21115003
[TBL] [Abstract][Full Text] [Related]
37. Mutations in the p53 tumor suppressor gene in tree shrew hepatocellular carcinoma associated with hepatitis B virus infection and intake of aflatoxin B1.
Park US; Su JJ; Ban KC; Qin L; Lee EH; Lee YI
Gene; 2000 Jun; 251(1):73-80. PubMed ID: 10863098
[TBL] [Abstract][Full Text] [Related]
38. PARK2 polymorphisms predict disease progression in patients infected with hepatitis C virus.
Al-Qahtani AA; Al-Anazi MR; Al-Zoghaibi FA; Abdo AA; Sanai FM; Al-Hamoudi WK; Alswat KA; Al-Ashgar HI; Khan MQ; Albenmousa A; Khalak H; Al-Ahdal MN
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):824-833. PubMed ID: 27740515
[TBL] [Abstract][Full Text] [Related]
39. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.
Nordgard SH; Ritchie MD; Jensrud SD; Motsinger AA; Alnaes GI; Lemmon G; Berg M; Geisler S; Moore JH; Lønning PE; Børresen-Dale AL; Kristensen VN
Pharmacogenet Genomics; 2007 Feb; 17(2):127-36. PubMed ID: 17301692
[TBL] [Abstract][Full Text] [Related]
40. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer.
Almquist LM; Karagas MR; Christensen BC; Welsh MM; Perry AE; Storm CA; Nelson HH
Carcinogenesis; 2011 Mar; 32(3):327-30. PubMed ID: 21123835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
